This site is intended for Healthcare professionals only.
×

Aurobindo Pharma receives USFDA Approval for Ibandronate Sodium Injection

Aurobindo Pharma receives USFDA Approval for Ibandronate Sodium Injection

At the estimate market size of $422 million for 12 months, the generic version of Prilosec delayed-release capsules by Aurobindo Pharma will be launched in the US

Aurobindo Pharma has received the green signal from the USFDA to market the generic version of Prilosec delayed-release capsule in the strengths of 10mg, 20mg, and 40 mg in the American market. The company has got the permission to manufacture and market Omeprazole delayed-release, used for short-term treatment of active duodenal ulcer in adults.

As confirmed by PTI,

The company’s approved abbreviated new drug application (ANDA) is a generic version of AstraZeneca Pharmaceuticals’ Prilosec capsules, confirmed the company in a media statement,
According to IMS, the product had an estimated market size of USD 422 million for the twelve months ended June 30.

In a separate statement, the company said it has received approval from the USFDA to market generic version of Hoffmann-La Roche’s Boniva injection in the American market.

The company’s Ibandronate Sodium injection is indicated for the treatment of osteoporosis in postmenopausal women.

0 comment(s) on Aurobindo Pharma receives USFDA Approval for Ibandronate Sodium Injection

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted
    Source: PTI

    Opinion Polls

    Should Government Doctors be allowed to do Private Practice?